Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/12/2019
SIETES contiene 92850 citas

 
 
 1 a 13 de 13 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Gao S-Y, Wu Q-J, Zhang T-N, Shen Z-Q, Liu C-X, Xu X, Ji C, Zhao Y-H. Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. Br J Clin Pharmacol 2017;83:2134. [Ref.ID 102080]
2.Enlace a cita original Cita con resumen
Shen Z-Q, Gao S-Y, Li SX, Zhang T-N, Liu C-X, Lv H-C, Zhang Y, Gong T-T, Xu X, Ji C, Wu Q-J, Li D. Sertraline use in the first trimester and risk of congenital anomalies: a systematic review and meta-analysis of cohort studies. Br J Clin Pharmacol 2017;83:909-22. [Ref.ID 101518]
3.
Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Xu X, Sklar P, for the SWITCHMRK1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407. [Ref.ID 87807]
4.Tiene citas relacionadas Cita con resumen
Lennox JL, DeJesus E, Lazzarín A, Pollard RB, Madruga J, Berger DS, Zhao J, Xu X, Williams-Díaz A, Rodgers AJ, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Sklar P, for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806. [Ref.ID 86738]
5. Cita con resumen
Balish A, Warnes CM, Wu K, Barnes N, Emery S, Berman L, Shu B, Lindstrom S, Xu X, Uyeki T, Shaw M, Klimov A, Villanueva J. Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) virus --- United States, 2009. MMWR Morb Mortal Wkly Rep 2009;58:826-9. [Ref.ID 86407]
6. Cita con resumen
Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, Xu X, Lindstrom S, Gubareva LV, Deyde V, Garten RJ, Harris M, Gerber S, Vagasky S, Smith F, Pascoe N, Martin K, Dufficy D, Ritger K, Conover C, Quinlisk P, Klimov A, Bresee JS, Finelli L. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009;360:2616-25. [Ref.ID 86056]
7.Tiene citas relacionadas
Wang X, Qin X, Demirtas H, Xu X. Folic acid for stroke prevention. Lancet 2007;370:651. [Ref.ID 80792]
8.Tiene citas relacionadas Cita con resumen
Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82. [Ref.ID 80193]
9.Tiene citas relacionadas Cita con resumen
Bright RA, Medina M-J, Xu X, Pérez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005;366:1175-81. [Ref.ID 74904]
11.Tiene citas relacionadas
Wang L, Chen D, Niu T, Wang Z, Wang L, Ryan L, Smith T, Christiani DC, Zuckerman B, Xu X. Genetic susceptibility to benzene and shortened gestation: evidence of gene-environment interaction. Am J Epidemiol 2000;152:693-700. [Ref.ID 53313]
12.
Knorr B, Larson P, Nguyen H H, Holland S, Reiss T F, Chervinsky P, Blake K, van Nispen CHM, Noonan G, Freeman A, Haesen R, Xu X, Seidenberg BC, Gertz BJ, Spielberg S. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol 1999;39:786-93. [Ref.ID 48352]
13.
Wang X, Wang M, Niu T, Chen C, Xu X. Microsomal epoxide hydrolase polymorphism and risk of spontaneous abortion. Epidemiology 1998;9:540-4. [Ref.ID 39701]
Seleccionar todas
 
 1 a 13 de 13